Analyze the time and space complexity of your solution. Compare your solution to others and identify areas for improvement.

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

The Darwin Godel Machine (DGM) is the first self-improving coding AI agent, using evolutionary programming and recursive self-improvement to autonomously enhance its capabilities.

Our C. diff program came out of our Recursion 1.0 platform, where we started to explore new chemical entities, and we see no reason today why the science doesn't continue to hold on that program.

All told, Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first ...

Recursion will receive $7 million from Sanofi after advancing the fourth of 15 planned programs into lead optimization phase in less than a year, as part of a collaboration that could generate ...

Philip Bakleski (Phiality) has published a paper on GitHub about a method called 'Chain of Recursive Thoughts (CoRT),' which allows an AI to think more deeply by repeatedly asking itself questions ...

Recursion's most advanced program is only in phase 1/2 testing. There's no guarantee that any of the pipeline candidates will be successful in clinical studies and win regulatory approvals.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...

Recursion trumpeted the results as if they were successful, but this program isn't going anywhere fast. The company still hasn't announced plans to launch a phase 3 study for REC-994, the ...

The fund will provide up to $250,000 in capital, 12 months of lab space and access to Altitude Lab’s accelerator program for biotech startups that have been reviewed for Small Business ...